7th Annual IBDHorizons Midwest Symposium

IBDHorizons is pleased to announce the 7th Annual IBD-focused Midwest Symposium, Back in Cincinnati
IBDHorizons provides free IBD conferences open to all those who treat IBD and desire to treat IBD.
At our 7th Annual Midwest IBD conference, you will learn from and engage in discourse about the latest in Inflammatory Bowel Disease (IBD) from world-renowned faculty, on Saturday, February 10, 2024.
During the IBDHorizons Midwest Symposium, you’ll be provided with a smooth experience including catered meals, thoughtful breaks throughout the day’s events, and a personal tablet to engage with the presentations. We dedicate more time than most other IBD conferences to our open panel discussions and real-world case studies to be examined alongside the faculty.
Our Midwest IBD conference will be hosted at the Hyatt Regency, 151 West 5th Street, Cincinnati, OH.
CME/CE/CPE
This IBDHorizons event is expected to be accredited for up to 6 CME, CE, and CPE credit hours for attendees.
Cost
Registration is required to plan accordingly, but registration for IBDHorizons Midwest is complimentary to attendees!
Join us for this amazing IBD conference opportunity to engage with notable leaders in the field of Inflammatory Bowel Disease (IBD).
Exhibits
IBDHorizons IBD-dedicated conference presents an excellent opportunity for industry exhibits. Please contact us for more information.
Agenda
Speakers and topics will be announced! As always, our IBD Founders and honorary board member Dr. Brian Feagan will be speaking.
Endoscopy and Ultrasound Lab
Due to popular request, IBDHorizons has continued its live hands-on endoscopy lab session. Live lab session includes demonstrations and hands-on format allowing participants to review and try the newest endoscopic technology including:
- Intestinal Ultrasound (IUS) for IBD
- Full thickness resection devices
- Endoscopic submucosal dissection
- Virtual chromo-endoscopy
- Standard endoscopic devices and technology
If you have registered for the in-person Midwest symposium, you will automatically be registered for this session.
Research Plenary Session
Returning this year is our Abstract presentations and Research Plenary Session. The deadline for submission of abstracts is January 20, 2024.
Date
Time
Location
Website
https://www.hyatt.com/en-US/hotel/ohio/hyatt-regency-cincinnati/cinciSpeakers
-
Anita Afzali, MD, MPH, MHCMProfessor of Medicine in the Division of Digestive Diseases, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System
Dr. Anita Afzali is a Professor of Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. She is also the Associate Chief Medical Officer of the UC Health System. She received her medical degree and then completed Internal Medicine residency and gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and graduated with a Masters in Public Health from The University of Washington. She then later obtained another Masters In Healthcare Management (MHCM) from Harvard T.H. Chan School of Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty.
While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. After Seattle, Dr. Afzali moved to Columbus, OH to be the Medical Director of The OSU IBD Center and the Vice Chair of Clinical Operations of Gastroenterology at The Ohio State University.
Recently, she has transitioned to the University of Cincinnati where she serves as the Executive Vice Chair of the Department of Internal Medicine. Her research interests include drug study design, investigational drug trials, and clinical outcomes. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Chair of the American College of Gastroenterology (ACG) Educational Affairs Committee and Vice Chair of Publications Committee for the World Gastroenterology Organization (WGO).
-
Brian Feagan, MD, MScProfessor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCF) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
-
Feza Remzi, MDColorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery at NYU School of Medicine
As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions.
Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states “I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team.”
As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease. -
Ghassan Wahbeh, MDDirector of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital
Ghassan Wahbeh, MD, is the Director of the Inflammatory Bowel Disease (IBD) Center at Seattle Children’s Hospital. He is a Professor of Pediatrics and Gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children, adolescents, and young adults with Crohn’s Disease and ulcerative colitis, including advanced therapeutics and pre and post-surgery IBD management.
Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies. Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training, and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohn’s and Colitis Foundation.
Dr. Ghassan Wahbeh is a co-founder of IBDHorizons
@PedsIBD_Wahbeh
-
Scott D. Lee, MDAssociate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center
Dr. Scott D. Lee is an Associate Professor of Medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCF), American Gastroenterology Association, American College of Gastroenterology, and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
